Loss of runt‐related transcription factor 3 induces gemcitabine resistance in pancreatic cancer

Runt‐related transcription factor 3 (RUNX3) is a tumor suppressor gene that is expressed in gastric and other cancers including pancreatic cancer. However, the precise function of RUNX3 in pancreatic cancer has not been fully elucidated. In this study, we aimed to determine the effect of decreased RUNX3 expression in pancreatic cancer.

[1]  G. Peters,et al.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines , 2003, British Journal of Cancer.

[2]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[3]  Jörg König,et al.  Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma , 2005, International journal of cancer.

[4]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Dong Tang,et al.  Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. , 2011, Oncology reports.

[6]  K. Chayama,et al.  Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. , 2008, International journal of oncology.

[7]  H. Takeuchi,et al.  Prognostic significance of the immunohistochemical expression of O6‐methylguanine‐DNA methyltransferase, P‐glycoprotein, and multidrug resistance protein‐1 in glioblastomas , 2009, Neuropathology : official journal of the Japanese Society of Neuropathology.

[8]  Yoshiaki Ito,et al.  RUNX3 is multifunctional in carcinogenesis of multiple solid tumors , 2010, Oncogene.

[9]  N. Lemoine,et al.  Pancreatic Cancer Genetics , 2001, Pancreatology.

[10]  R. Hruban,et al.  An Introduction to Pancreatic Adenocarcinoma Genetics, Pathology and Therapy , 2002, Cancer biology & therapy.

[11]  Manuel Salto-Tellez,et al.  Molecular pathology of RUNX3 in human carcinogenesis. , 2009, Biochimica et biophysica acta.

[12]  S. Itohara,et al.  Causal Relationship between the Loss of RUNX3 Expression and Gastric Cancer , 2002, Cell.

[13]  Scott E Kern,et al.  Focus on pancreas cancer. , 2002, Cancer cell.

[14]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  S. Bae,et al.  Tumor suppressor activity of RUNX3 , 2004, Oncogene.

[16]  H. Sugimoto,et al.  Adverse prognosis of epigenetic inactivation in RUNX3 gene at 1p36 in human pancreatic cancer , 2008, British Journal of Cancer.

[17]  R. Ueda,et al.  The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.

[18]  C. Sakakura,et al.  Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines , 2003, Oncogene.

[19]  Lijun Sun,et al.  Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl‐2, MDR‐1 and MRP‐1 , 2005, International journal of cancer.

[20]  M. Mimeault,et al.  Recent Advances on the Molecular Mechanisms Involved in Pancreatic Cancer Progression and Therapies , 2005, Pancreas.

[21]  H. Friess,et al.  RUNX3 expression in primary and metastatic pancreatic cancer , 2004, Journal of Clinical Pathology.

[22]  Kosei Ito.  RUNX3 in oncogenic and anti‐oncogenic signaling in gastrointestinal cancers , 2011, Journal of cellular biochemistry.

[23]  Donghui Li,et al.  Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome , 2011, Cancer.

[24]  H. Ueno,et al.  Phase I trial of gemcitabine in patients with advanced pancreatic cancer. , 2001, Japanese journal of clinical oncology.

[25]  E. Giovannetti,et al.  Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer , 2006, Molecular Cancer Therapeutics.

[26]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[27]  Y. Nakanishi,et al.  Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis , 2011, BMC Cancer.

[28]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[29]  Jing Wen,et al.  CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells , 2009, International journal of cancer.

[30]  W. Hagmann,et al.  Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. , 2010, Neoplasia.

[31]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[33]  R. Langer,et al.  High pretherapeutic thymidylate synthetase and MRP‐1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients , 2010, Journal of surgical oncology.

[34]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[35]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[36]  R. Jesenofsky,et al.  ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines , 2008, Pancreatology.

[37]  K. Faber,et al.  Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia , 2005, Clinical Cancer Research.

[38]  D. V. Von Hoff,et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.